Lonza launches liver cells for biopharma research

By Staff reporter

- Last updated on GMT

Lonza has launched a new range of cryopreserved liver cells for biopharmaceutical companies that want to assess the toxicity of their drugs.

The cell lines – which consist of human and animal hepatocytes– are designed for use in a variety of in-vitro​ applications, including studies into drug metabolism and toxicity, drug-transporter activity and drug-drug interactions.

A Lonza spokeswoman told us “These high-quality hepatocytes will support scientists with in-vitro​ drug metabolism and pharmacokinetic studies, as well as vital research into diseases such as Malaria and Hepatitis B.”

In addition, the Swiss life sciences supplier has developed supporting ADME-Tox products such as specialized hepatocyte media and cell culture systems.

The launch comes a year after Lonza bought​ US liver cell specialist Triangle Research Laboratories, whose role in the launch was acknowledged by Maureen Bunger, product manager for ADME-Tox Solutions.

By blending the extensive expertise of Lonza and TRL, our new hepatocyte portfolio will address the needs of the scientific community, offering hepatocytes that produce consistent and reliable results for ADME-Tox testing and for research into liver-associated diseases​.”

Related news

Show more

Related products

show more

Related suppliers

Follow us